Alliance for Cancer Gene Therapy

About Alliance for Cancer Gene Therapy

Every year in the U.S., nearly 2 million are diagnosed with cancer. Traditional cancer surgery, chemotherapy and radiation give patients precious moments but no long-term promise. New cancer therapies using the body’s own cells and genes are changing this. In 2001, Alliance for Cancer Gene Therapy became one of the first and only organizations to embrace a progressive vision for the underfunded but exceptionally promising discipline of cancer cell and gene therapy. The organization quickly became a catalytic force in shaping entirely new cancer treatment models by identifying, funding, and advancing the most innovative and impactful translational research in cell and gene therapies. To date, we have awarded more than $30 million in grants to world class cancer researchers representing the top medical institutions in the U.S. and Canada, advancing new approaches to leukemia, lymphoma, ovarian, prostate, sarcoma, glioblastoma, melanoma, lung and pancreatic cancers. It’s time for another breakthrough: Today there is an urgent need to translate the profound success of CAR T-cell therapies for blood cancers into successful therapies for the most complex and deadly cancers – solid tumor cancers. Current funding priorities work to tackle pancreatic cancer and brain cancer, and to advance the understanding of solid tumor biology that will lead to curative therapies. Help advance our vision for a cure to all cancers. 100% of public donations directly support frontline scientists and programs working on thoroughly vetted and responsibly monitored cancer cell and gene therapy research enabling Alliance for Cancer Gene Therapy to award $34.2 million through 67 grants to 63 innovative researchers, representing 38 top medical institutions in the U.S. and Canada.